European Commission explains quality data needed for biologicals trials
This article was originally published in SRA
Executive Summary
The European Commission has adopted a final guideline specifying the data on quality that drug companies must submit when seeking permission to conduct clinical trials of an investigational product containing biological/biotechnology-derived substances1.